Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
41 hedge funds and large institutions have $2.35M invested in Carisma Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
11% more funds holding
Funds holding: 37 → 41 (+4)
0.94% more ownership
Funds ownership: 12.53% → 13.47% (+0.94%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
54% less capital invested
Capital invested by funds: $5.11M → $2.35M (-$2.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$30.4K |
| 2 |
Renaissance Technologies
New York
|
+$20.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$19.8K |
| 4 |
Goldman Sachs
New York
|
+$17.6K |
| 5 |
LPL Financial
San Diego,
California
|
+$17.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$551K |
| 2 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$34.2K |
| 3 |
Two Sigma Investments
New York
|
-$33.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.2K |
| 5 |
Millennium Management
New York
|
-$18.4K |
CARM Hedge Fund Activity: Q4 2024 in Review
41 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2024, worth a combined $2.35M — down 54% from $5.11M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CARM positions and 9 closed out — a net gain of 5 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $30.4K. The largest seller was TPG GP A, exiting entirely with an estimated $551K sold.
- 41 institutional investors held Carisma Therapeutics (CARM) as of Q4 2024, up from 37 in Q3 2024.
- Funds reported $2.35M of Carisma Therapeutics stock for Q4 2024, down 54% quarter-over-quarter.
- 14 funds opened new Carisma Therapeutics positions in Q4 2024 and 9 closed out, a net change of +5 holders.
- The largest Carisma Therapeutics buyer in Q4 2024 was HRT Financial, an estimated $30.4K added.
- The largest Carisma Therapeutics seller in Q4 2024 was TPG GP A, an estimated $551K sold.
Based on aggregated 13F filings for Q4 2024.